HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

monoclonal antibody CNTO 1275 (CNTO 1275)

entering phase II development; may prove useful in treating psoriasis
Also Known As:
CNTO 1275; CNTO-1275; monoclonal antibody CNTO-1275; ustekinumab
Networked: 429 relevant articles (109 outcomes, 119 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1. Gottlieb, Alice B: 15 articles (08/2015 - 06/2010)
2. Yeilding, Newman: 15 articles (08/2012 - 05/2008)
3. Szapary, Philippe: 13 articles (10/2015 - 05/2008)
4. Feldman, Steven R: 12 articles (12/2015 - 07/2010)
5. Li, Shu: 12 articles (10/2015 - 05/2008)
6. Langley, Richard G: 11 articles (10/2015 - 05/2008)
7. Schenkel, Brad: 11 articles (04/2015 - 09/2010)
8. Puig, L: 11 articles (03/2015 - 09/2010)
9. Menter, Alan: 10 articles (10/2015 - 02/2009)
10. Zhou, Honghui: 10 articles (08/2014 - 02/2009)

Related Diseases

1. Psoriasis (Pustulosis Palmaris et Plantaris)
2. Psoriatic Arthritis
3. Crohn Disease (Crohn's Disease)
4. Necrosis
5. Arthritis (Polyarthritis)

Related Drugs and Biologics

1. Interleukin-12 (IL 12)
2. TNFR-Fc fusion protein (etanercept)
3. Interleukin-23 (Interleukin 23)
4. adalimumab (Humira)
5. adjuvant P40 (P 40)
6. infliximab (Remicade)
7. Interleukins
8. golimumab
9. briakinumab
10. Antibodies

Related Therapies and Procedures

1. Subcutaneous Injections
2. Transplants (Transplant)
3. Injections
4. Phototherapy (Light Therapy)
5. Chemoprevention